Diabetologie und Stoffwechsel 2019; 14(S 01): S85
DOI: 10.1055/s-0039-1688355
Poster
SGLT2-Inhibitoren und GLP1-Agonisten
Georg Thieme Verlag KG Stuttgart · New York

Efficacy of semaglutide vs. dulaglutide across baseline HbA1c in SUSTAIN 7

W Schmidt
1   St. Josef-Hospital Klinikum der Ruhr-Universität Bochum, St. Josef-Hospital Klinikum der Ruhr-Universität Bochum, Bochum, Germany
,
R Pratley
2   Florida Hospital Translational Research Institute, Florida Hospital Translational Research Institute, FL, United States
,
J Frias
3   National Research Institute, National Research Institute, LA, United States
,
H Kumar
4   Centre for Endocrinology and Diabetes, Amrita Vishwa Vidyapeetham, Centre for Endocrinology and Diabetes, Amrita Vishwa Vidyapeetham, Kochi, India
,
J Petrie
5   Institute of Cardiovascular and Medical Sciences, University of Glasgow, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
,
A Navarria
6   Novo Nordisk A/S, Novo Nordisk A/S, Søborg, Denmark
,
M Nielsen
6   Novo Nordisk A/S, Novo Nordisk A/S, Søborg, Denmark
,
J Schwensen
6   Novo Nordisk A/S, Novo Nordisk A/S, Søborg, Denmark
› Author Affiliations
Further Information

Publication History

Publication Date:
07 May 2019 (online)

Also available at
 
 

    Semaglutide a glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes (T2D) showed significant and clinically meaningful HbA1c and body weight reductions across the SUSTAIN programme. This post hoc analysis of the phase 3b SUSTAIN 7 trial evaluated semaglutide 0.5 mg vs. dulaglutide 0.75 mg and semaglutide 1.0 mg vs. dulaglutide 1.5 mg by baseline HbA1c in subjects with T2D.

    Methods:

    Efficacy data from SUSTAIN 7 were evaluated; subjects were stratified by baseline HbA1c (≤7.5%, 7.5 – 8.0%, 8.0 – 8.5%, 8.5 – 9.0%, > 9.0%). For treatment target endpoints, missing data were imputed from a mixed model for repeated measurements.

    Results:

    At week 40, greater reductions in HbA1c were observed with semaglutide vs. dulaglutide across subgroups. Changes from BL in body weight favoured semaglutide 0.5 mg vs. dulaglutide 0.75 mg and semaglutide 1.0 mg vs. dulaglutide 1.5 mg; no significant interaction between treatment and BL HbA1c were observed. More subjects with BL HbA1c > 9% achieved HbA1c < 7% with semaglutide 0.5 mg vs. dulaglutide 0.75 mg (44 vs. 18%) and semaglutide 1.0 mg vs. dulaglutide 1.5 mg (55 vs. 34%). Similarly, more subjects with BL HbA1c > 9% achieved HbA1c ≤6.5% with semaglutide 0.5 mg vs. dulaglutide 0.75 mg (32 vs. 9%) and semaglutide 1.0 mg vs. dulaglutide 1.5 mg (41 vs. 20%).

    Conclusion:

    Greater reductions in HbA1c and body weight were observed with semaglutide vs. dulaglutide in all subjects regardless of BL HbA1c.


    #